Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
A new study published on the preprint site medRxiv in May 2020 reports on the efficacy of interferons in treating COVID-19. The research could help evaluate the place of such therapy in the management of this disease.
Since the outbreak of the COVID-19 pandemic and its rapid spread, the scientific community has been working on developing an effective treatment for the virus responsible for the disease.
As the world struggles to overcome the current COVID-19 pandemic with non-pharmacological interventions, in the absence of an effective drug or vaccine, existing immunomodulators are being repurposed. A new study published on the preprint server medRxiv* in May 2020 shows no clinical benefit to the use of one such drug, called interferon beta 1b (IFN beta1b).
A new study published on the preprint server medRxiv* in May 2020 reports the beneficial effects of the monoclonal antibody sarilumab in severe COVID-19 pneumonia.
Although scientists and stock markets have celebrated the approval for emergency use of remdesivir to treat COVID-19, a cure for the disease that has killed nearly 260,000 people remains a long way off — and might never arrive.
The world has experienced many outbreaks of viral diseases. Over the past two decades, we have also seen the emergence of zoonotic human respiratory coronaviruses with pandemic potential.
A new study published in the journal Science Immunology in May 2020 reports that compounds that safely inhibit the JAK protein could be useful in treating COVID-19.
The skyrocketing number of cases due to the coronavirus pandemic has taken a massive toll on the health systems in many countries. Since the advent of the coronavirus disease (COVID-19), hundred of research teams are racing to find an effective vaccine and treatment to combat the deadly infection. Now, a team of researchers in Hong Kong suggests that combining three existing antivirals may help treat COVID-19 patients.
A team of scientists from St. Michael's Hospital, Sinai Health and Sunnybrook Health Sciences Centre have launched a clinical trial to understand whether an existing drug used for HIV treatment and prevention may work to prevent COVID-19 infection.
The coronavirus disease (COVID-19) is potentially fatal for vulnerable populations like seniors who over 60 years old, and those with underlying medical conditions, like heart disease, diabetes, and lung disease. Reports show that patients are suffering from heart impairment caused by COVID-19. A new study sheds light on the effect of the novel coronavirus on the heart, causing cardiovascular problems, even in those without underlying heart conditions.
A new review paper published in the preprint open-access journal medRxiv in April 2020 reports that there is not enough evidence to justify the widespread use of the drug hydroxychloroquine (HCQ) in the treatment or prophylaxis of the current COVID-19 illness.
With the stepwise easing of measures in Switzerland, it is pivotal to monitor for any new COVID-19 outbreaks and to contain them in a timely and effective manner.
An exploratory randomized, controlled study on the safety and efficacy of either lopinavir/ritonavir (LPV/r) or Arbidol--antivirals that are used in some countries against HIV-1 and to treat influenza , respectively--as treatments for COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, suggests that neither drug improves the clinical outcome of patients hospitalized with mild-to-moderate cases of the disease over supportive care.
A new study published in the journal bioRxiv in April 2020 reports the identification of a promising multidrug treatment against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for causing COVID-19 disease. The team predicts that this combination will prevent the virus from reproducing, hence both halting the transmission and progress of the disease.
Q (Prof. Singer): What do you think about the comorbidities and the age of the patients in the treatment of COVID-19? Is the mortality higher in elderly patients as it is reported from recent papers?
The paper looks at repurposed drugs that might demonstrate efficacy against COVID-19, and if they could be manufactured profitably at very low costs to ensure affordable access to vital treatments for COVID-19 at low prices globally.
The coronavirus disease (COVID-19) has no approved treatment or vaccine as the world grapple with its wrath. The viral infection has so far infected 1.8 million and killed more than 114,000 people. Now, a team of scientists has shown that an experimental antiviral drug, remdesivir, has shown promise in treating patients with severe COVID-19.
All over the world, except in China, the place where it all began, the COVID-19 pandemic is making its relentless way through the population. So far, it has caused nearly 34,000 deaths – and the situation in the US is still worsening with over 142,000 cases and 2,489 deaths. In Australia, the number of cases has climbed to 4,093, with 16 fatalities.
SARS-CoV-2, the virus that causes COVID-19, continues to spread, leading to more than 20,000 deaths worldwide in less than four months. Efforts are progressing to develop a COVID-19 vaccine, but it's still likely 12 to 18 months away.
The U.K. government backs six projects aimed to fight the coronavirus outbreak, promising $23 million (£20 million) in funding. The projects, including two focused on vaccination trials, will help fast track the development of a vaccine to stop the spread of the coronavirus, leading to the death of more than 16,500 people across the globe.